These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Current status and challenges associated with targeting mTOR for cancer therapy. Dowling RJ; Pollak M; Sonenberg N BioDrugs; 2009; 23(2):77-91. PubMed ID: 19489650 [TBL] [Abstract][Full Text] [Related]
6. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080 [TBL] [Abstract][Full Text] [Related]
7. New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma. Agulnik M Cancer; 2012 Mar; 118(6):1486-97. PubMed ID: 21837674 [TBL] [Abstract][Full Text] [Related]
8. Targeting the mTOR pathway using deforolimus in cancer therapy. Mahalingam D; Sankhala K; Mita A; Giles FJ; Mita MM Future Oncol; 2009 Apr; 5(3):291-303. PubMed ID: 19374536 [TBL] [Abstract][Full Text] [Related]
9. Targeting the molecular target of rapamycin (mTOR). Rowinsky EK Curr Opin Oncol; 2004 Nov; 16(6):564-75. PubMed ID: 15627018 [TBL] [Abstract][Full Text] [Related]
10. Enhancing mTOR-targeted cancer therapy. Wang X; Sun SY Expert Opin Ther Targets; 2009 Oct; 13(10):1193-203. PubMed ID: 19694499 [TBL] [Abstract][Full Text] [Related]
11. mTOR signaling and drug development in cancer. Dancey J Nat Rev Clin Oncol; 2010 Apr; 7(4):209-19. PubMed ID: 20234352 [TBL] [Abstract][Full Text] [Related]
12. Targeting mTOR for cancer treatment. Rubio-Viqueira B; Hidalgo M Adv Exp Med Biol; 2006; 587():309-27. PubMed ID: 17163174 [TBL] [Abstract][Full Text] [Related]
13. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Zhang YJ; Duan Y; Zheng XF Drug Discov Today; 2011 Apr; 16(7-8):325-31. PubMed ID: 21333749 [TBL] [Abstract][Full Text] [Related]
14. Mammalian target of rapamycin: a new molecular target for breast cancer. Mita MM; Mita A; Rowinsky EK Clin Breast Cancer; 2003 Jun; 4(2):126-37. PubMed ID: 12864941 [TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Gibbons JJ; Abraham RT; Yu K Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098 [TBL] [Abstract][Full Text] [Related]
16. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Rao RD; Buckner JC; Sarkaria JN Curr Cancer Drug Targets; 2004 Dec; 4(8):621-35. PubMed ID: 15578919 [TBL] [Abstract][Full Text] [Related]
17. Recent patents and patent applications relating to mTOR pathway. Liu X; Yue Z Recent Pat DNA Gene Seq; 2009; 3(1):44-52. PubMed ID: 19149738 [TBL] [Abstract][Full Text] [Related]
18. Recent clinical trials of mTOR-targeted cancer therapies. Don AS; Zheng XF Rev Recent Clin Trials; 2011 Jan; 6(1):24-35. PubMed ID: 20868343 [TBL] [Abstract][Full Text] [Related]
19. Impact of genetic alterations on mTOR-targeted cancer therapy. Sun SY Chin J Cancer; 2013 May; 32(5):270-4. PubMed ID: 23489586 [TBL] [Abstract][Full Text] [Related]
20. Current and future directions in mammalian target of rapamycin inhibitors development. Fasolo A; Sessa C Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]